ESSA Pharma Inc Stock

$1.91

0.00% yesterday

Nasdaq, Aug 12, 10:00 pm CET

ISIN

CA29668H7085

Symbol

EPIX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

ESSA Pharma Inc Stock price

$1.91

-4.86 71.79% 5Y

Nasdaq, Closing price Tue, Aug 12 2025

+0.00 0.00%

ISIN

CA29668H7085

Symbol

EPIX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$84.7m

Enterprise Value

$-29.2m

Net debt

positive

Cash

$113.9m

Shares outstanding

44.4m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

1.3

P/B

0.8

Financial Health

Equity Ratio

97.7%

Return on Equity

-22.8%

ROCE

-29.4%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-33.3m | -

EBIT

$-33.4m | $-33.6m

Net Income

$-28.5m | $-32.2m

Free Cash Flow

$-22.4m

EPS

$-0.6

FCF per Share

$-0.5

Short interest

2.0%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

ESSA Pharma Inc Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a ESSA Pharma Inc forecast:

4x Hold

57%

3x Sell

43%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a ESSA Pharma Inc forecast:

Hold

57%

Sell

43%

Analyst Estimates with Stock Price Targets

Financial data from ESSA Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	0.13 0.13	550% 550% -
Gross Profit	-0.13 -0.13	550% 550% -
- Selling and Administrative Expenses	15 15	29% 29% -
- Research and Development Expense	18 18	20% 20% -
EBITDA	-33 -33	- -
- Depreciation and Amortization	0.14 0.14	- -
EBIT (Operating Income) EBIT	-33 -33	2% 2% -
Net Profit	-29 -29	3% 3% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

ESSA Pharma Inc Stock News

Neutral

PRNewsWire

●

6 days ago

Essa Pharma Inc. Announces US$80 Million Cash Distribution to Shareholders

SOUTH SAN FRANCISCO, Calif and VANCOUVER, Canada , Aug. 6, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, following the Company's receipt of an order from the Supreme Court of British Columbia (the "Court") on August 5, 2025, authorizing a reduction in the capital of the common shares of the Company (the "Common Shares" and the holders of s...

Neutral

PRNewsWire

●

20 days ago

ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Approval of an Interim Order and Cash Distribution to Shareholders

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , July 23, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in connection with its previously announced business combination agreement with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire (the "Transaction") all of the issued and outstanding commo...

Neutral

Business Wire

●

29 days ago

EPIX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of ESSA Pharma Inc. is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ESSA Pharma Inc. (NASDAQ: EPIX) to XenoTherapeutics, Inc. is fair to ESSA shareholders. Halper Sadeh encourages ESSA shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zha...

More ESSA Pharma Inc News

Company Profile

ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

Head office	Canada
CEO	David Parkinson
Employees	35
Founded	2009
Website	www.essapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now